Alexandra Paravisini
Madrid, MD 28050, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phase III Study to Confirm Clinical Similarity of MB09, a Denosumab Biosimilar, and Prolia® in Postmenopausal Women with Osteoporosis (SIMBA Study).
Journal: Pharmaceutics
Published: January 27, 2026
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Journal: Pharmacology research & perspectives
Published: February 08, 2023
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 20, 2021
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Journal: Leukemia & lymphoma
Published: July 06, 2019
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Journal: The lancet. Gastroenterology & hepatology
Published: July 23, 2018
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Journal: Cancer chemotherapy and pharmacology
Published: September 28, 2017
Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Journal: Transplant international : official journal of the European Society for Organ Transplantation
Published: February 10, 2016
The Burden Of Chronic Urticaria In Europe: A Systematic Literature Review.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
Journal: Journal of investigational allergology & clinical immunology
Published: August 24, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026